AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT01434186
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01432392
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
Phase 1
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT01431690
Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct
Completed
- Conditions
- Asthma,Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2012-03-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 310
- Registration Number
- NCT01426893
- Locations
- 🇷🇸
Research Site, Sremska Kamenica, Serbia
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 231
- Registration Number
- NCT01425294
- Locations
- 🇨🇳
Research Site, Zhoushan, Zhejiang, China
Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: LAS100977 1.25 μgDrug: LAS100977 0.313 μgDrug: LAS100977 0.625 μgDrug: LAS100977 2.5 μgDrug: LAS100977 placebo
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT01425801
- Locations
- 🇩🇪
Almirall Investigational Sites#5, Wiesbaden, Germany
🇩🇪Almirall Investigational Sites#6, Berlin, Germany
🇩🇪Almirall Investigational Sites#4, Berlin, Germany
Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 87
- Registration Number
- NCT01425814
- Locations
- 🇩🇪
Almirall Investigational Sites#6, Frankfurt, Germany
🇩🇪Almirall Investigational Sites#3, Grosshansdorf, Germany
🇩🇪Almirall Investigational Sites#8, Lübeck, Germany
Magnitude of Osteoarthritis disadVantage on pEoples liveS
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1015
- Registration Number
- NCT01423097
- Locations
- 🇵🇹
Research Site, Queluz Baixo, Barcarena, Portugal
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2012-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT01419600
- Locations
- 🇬🇧
Research Site, London, UK, United Kingdom
Bioequivalence of Bicalutamide New Formulation in Japan
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT01416870